Circulating level of lipocalin 2 as a predictor of severity in patients with community-acquired pneumonia

Journal of Clinical Laboratory Analysis

Volumn 27, Issue 4, 2013, Pages 253-260

  Yeh, Yuan Hung ^a,b   Chang, Junn Liang ^c,d,e   Hsiao, Pei Ching ^a,f   Tsao, Shih Ming ^a,f   Lin, Chien Huang ^g   Kao, Shang Jyh ^h   Chou, Ming Chih ^a   Yang, Shun Fa ^a,f   Chien, Ming Hsien ^i,j  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b Yang Ming Rehabilitation Clinic   (Taiwan)

^c TAOYUAN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^d MING CHUAN UNIVERSITY   (Taiwan)

^e NATIONAL DEFENSE MEDICAL CENTER   (Taiwan)

^f CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^g TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^h SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

ⁱ TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^j TAIPEI MEDICAL UNIVERSITY   (Taiwan)

more..

Author keywords

Community acquired pneumonia; Lipocalin 2; Matrix metalloprotease 9; Pneumonia Severity Index

Indexed keywords

AMOXICILLIN; C REACTIVE PROTEIN; GELATINASE B; LEVOFLOXACIN; MOXIFLOXACIN; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; UREA;

ADULT; ANTIBIOTIC THERAPY; APACHE; ARTICLE; BLOOD PRESSURE; BREATHING RATE; CLINICAL ASSESSMENT TOOL; COMMUNITY ACQUIRED PNEUMONIA; COMPLEX FORMATION; CONFUSION; CONTROLLED STUDY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HOSPITAL PATIENT; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; NEUTROPHIL COUNT; PNEUMOTO SEVERITY INDEX; PREDICTION; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; SMOKING; UREA BLOOD LEVEL;

COMMUNITY-ACQUIRED PNEUMONIA; LIPOCALIN 2; MATRIX METALLOPROTEASE-9; PNEUMONIA SEVERITY INDEX;

ACUTE-PHASE PROTEINS; ADULT; AGED; ANTI-BACTERIAL AGENTS; APACHE; C-REACTIVE PROTEIN; COMMUNITY-ACQUIRED INFECTIONS; FEMALE; HUMANS; LEUKOCYTE COUNT; LIPOCALINS; MALE; MATRIX METALLOPROTEINASE 9; MIDDLE AGED; NEUTROPHILS; PNEUMONIA; PROTO-ONCOGENE PROTEINS; SEVERITY OF ILLNESS INDEX; TAIWAN;

EID: 84880383786     PISSN: 08878013     EISSN: 10982825     Source Type: Journal    
DOI: 10.1002/jcla.21588     Document Type: Article

References (51)

1. Pinner RW, Teutsch SM, Simonsen L, et al. Trends in infectious diseases mortality in the United States. JAMA 1996;275:189-193.
2. Lee YT, Chen SC, Shyu LY, et al. Significant elevation of plasma cathepsin B and cystatin C in patients with community-acquired pneumonia. Clin Chim Acta 2012;413:630-635.
3. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA 2005;294:2712-2719.
4. Thomsen RW, Riis A, Norgaard M, et al. Rising incidence and persistently high mortality of hospitalized pneumonia: A 10-year population-based study in Denmark. J Intern Med 2006;259:410-417.
5. Houck PM, Bratzler DW, Nsa W, Ma A, Bartlett JG. Timing of antibiotic administration and outcomes for Medicare patients hospitalized with community-acquired pneumonia. Arch Intern Med 2004;164:637-644.
6. Kanwar M, Brar N, Khatib R, Fakih MG. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: Side effects of the 4-h antibiotic administration rule. Chest 2007;131:1865-1869.
7. Tetley TD. New perspectives on basic mechanisms in lung disease. 6. Proteinase imbalance: Its role in lung disease. Thorax 1993;48:560-565.
8. Atkinson JJ, Senior RM. Matrix metalloproteinase-9 in lung remodeling. Am J Respir Cell Mol Biol 2003;28:12-24.
9. Lukkarinen H, Hogmalm A, Lappalainen U, Bry K. Matrix metalloproteinase-9 deficiency worsens lung injury in a model of bronchopulmonary dysplasia. Am J Respir Cell Mol Biol 2009;41:59-68.
10. Torii K, Iida K, Miyazaki Y, et al. Higher concentrations of matrix metalloproteinases in bronchoalveolar lavage fluid of patients with adult respiratory distress syndrome. Am J Respir Crit Care Med 1997;155:43-46.
11. Choi KH, Lee HB, Jeong MY, et al. The role of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in cryptogenic organizing pneumonia. Chest 2002;121:1478-485.
12. Segura-Valdez L, Pardo A, Gaxiola M, Uhal BD, Becerril C, Selman M. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000;117:684-694.
13. Piesiak P, Brzecka A, Kosacka M, Passowicz-Muszynska E, Dyla T, Jankowska R. Concentrations of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinases-1 in serum of patients with chronic obstructive pulmonary disease. Pol Merkur Lekarski 2011;31:270-273.
14. Cowland JB, Borregaard N. Molecular characterization and pattern of tissue expression of the gene for neutrophil gelatinase-associated lipocalin from humans. Genomics 1997;45:17-23.
15. Bratt T. Lipocalins and cancer. Biochim Biophys Acta 2000;1482:318-326.
16. Saiga H, Nishimura J, Kuwata H, et al. Lipocalin 2-dependent inhibition of mycobacterial growth in alveolar epithelium. J Immunol 2008;181:8521-8527.
17. Devarajan P. Neutrophil gelatinase-associated lipocalin (NGAL): A new marker of kidney disease. Scand J Clin Lab Invest Suppl 2008;241:89-94.
18. Bolignano D, Donato V, Lacquaniti A, et al. Neutrophil gelatinase-associated lipocalin (NGAL) in human neoplasias: A new protein enters the scene. Cancer Lett 2010;288:10-16.
19. Lin CW, Tseng SW, Yang SF, et al. Role of lipocalin 2 and its complex with matrix metalloproteinase-9 in oral cancer. Oral Dis 2012;18:734-740.
20. Bolignano D, Della Torre A, Lacquaniti A, Costantino G, Fries W, Buemi M. Neutrophil gelatinase-associated lipocalin levels in patients with crohn disease undergoing treatment with infliximab. J Investig Med 2010;58:569-571.
21. Devarajan P. NGAL in acute kidney injury: From serendipity to utility. Am J Kidney Dis 2008;52:395-399.
22. Ding L, Hanawa H, Ota Y, et al. Lipocalin-2/neutrophil gelatinase-B associated lipocalin is strongly induced in hearts of rats with autoimmune myocarditis and in human myocarditis. Circ J 2010;74:523-530.
23. Gupta K, Shukla M, Cowland JB, Malemud CJ, Haqqi TM. Neutrophil gelatinase-associated lipocalin is expressed in osteoarthritis and forms a complex with matrix metalloproteinase 9. Arthritis Rheum 2007;56:3326-3335.
24. Tsai HT, Su PH, Lee TH, et al. Significant elevation and correlation of plasma neutrophil gelatinase associated lipocalin and its complex with matrix metalloproteinase-9 in patients with pelvic inflammatory disease. Clin Chim Acta 2011;412:1252-1256.
25. Chan YR, Liu JS, Pociask DA, et al., Lipocalin 2 is required for pulmonary host defense against Klebsiella infection. J Immunol 2009;182:4947-4956.
26. Gupta N, Krasnodembskaya A, Kapetanaki M, et al., Mesenchymal stem cells enhance survival and bacterial clearance in murine Escherichia coli pneumonia. Thorax 2012;67:533-539.
27. Srinivasan G, Aitken JD, Zhang B, et al., Lipocalin 2 deficiency dysregulates iron homeostasis and exacerbates endotoxin-induced sepsis. J Immunol 2012;189:1911-1919.
28. Chakraborty S, Kaur S, Muddana V, et al. Elevated serum neutrophil gelatinase-associated lipocalin is an early predictor of severity and outcome in acute pancreatitis. Am J Gastroenterol 2010;105:2050-2059.
29. Yan L, Borregaard N, Kjeldsen L, Moses MA. The high molecular weight urinary matrix metalloproteinase (MMP) activity is a complex of gelatinase B/MMP-9 and neutrophil gelatinase-associated lipocalin (NGAL). Modulation of MMP-9 activity by NGAL. J Biol Chem 2001;276:37258-37265.
30. Fernandez CA, Yan L, Louis G, Yang J, Kutok JL, Moses MA. The matrix metalloproteinase-9/neutrophil gelatinase-associated lipocalin complex plays a role in breast tumor growth and is present in the urine of breast cancer patients. Clin Cancer Res 2005;11:5390-5395.
31. Smith ER, Zurakowski D, Saad A, Scott RM, Moses MA. Urinary biomarkers predict brain tumor presence and response to therapy. Clin Cancer Res 2008;14:2378-2386.
32. Kubben FJ, Sier CF, Hawinkels LJ, et al. Clinical evidence for a protective role of lipocalin-2 against MMP-9 autodegradation and the impact for gastric cancer. Eur J Cancer 2007;43:1869-1876.
33. Haase-Fielitz A, Bellomo R, Devarajan P, et al. The predictive performance of plasma neutrophil gelatinase-associated lipocalin (NGAL) increases with grade of acute kidney injury. Nephrol Dial Transplant 2009;24:3349-3354.
34. Mandell LA, Wunderink RG, Anzueto A, et al. Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin Infect Dis 2007;44(Suppl 2):S27-S72.
35. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med 1997;336:243-250.
36. Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: A severity of disease classification system. Crit Care Med 1985;13:818-829.
37. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: An international derivation and validation study. Thorax 2003;58:377-382.
38. Cruz DN, de Cal M, Garzotto F, et al. Plasma neutrophil gelatinase-associated lipocalin is an early biomarker for acute kidney injury in an adult ICU population. Intensive Care Med 2010;36:444-451.
39. Chalmers JD, Singanayagam A, Hill AT. C-reactive protein is an independent predictor of severity in community-acquired pneumonia. Am J Med 2008;121:219-225.
40. Jeong KY, Kim K, Kim TY, et al. Prognostic value of N-terminal pro-brain natriuretic peptide in hospitalised patients with community-acquired pneumonia. Emerg Med J 2011;28:122-127.
41. Muller F, Christ-Crain M, Bregenzer T, et al. Procalcitonin levels predict bacteremia in patients with community-acquired pneumonia: A prospective cohort trial. Chest 2010;138:121-129.
42. Chiang TY, Shyu LY, Tsao TC, et al. Elevated plasma matrix metalloproteinase-9 protein and its gene polymorphism in patients with community-acquired pneumonia. Clin Chem Lab Med 2012;50:449-454.
43. Arnold FW, Brock GN, Peyrani P, et al. Predictive accuracy of the pneumonia severity index vs CRB-65 for time to clinical stability: Results from the Community-Acquired Pneumonia Organization (CAPO) International Cohort Study. Respir Med 2010;104:1736-1743.
44. Cilloniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax 2011;66:340-346.
45. Kollef KE, Reichley RM, Micek ST, Kollef MH. The modified APACHE II score outperforms CURB65 pneumonia severity score as a predictor of 30-day mortality in patients with methicillin-resistant Staphylococcus aureus pneumonia. Chest 2008;133:363-369.
46. Richards G, Levy H, Laterre PF, et al. CURB-65, PSI, and APACHE II to assess mortality risk in patients with severe sepsis and community acquired pneumonia in PROWESS. J Intens Care Med 2011;26:34-40.
47. Muller B, Harbarth S, Stolz D, et al. Diagnostic and prognostic accuracy of clinical and laboratory parameters in community-acquired pneumonia. BMC Infect Dis 2007;7:1-10.
48. Niederman MS, Feldman C, Richards GA. Combining information from prognostic scoring tools for CAP: An American view on how to get the best of all worlds. Eur Respir J 2006;27:9-11.
49. Singanayagam A, Chalmers JD, Hill AT. Severity assessment in community-acquired pneumonia: A review. QJM 2009;102:379-388.
50. Polzin A, Pletz M, Erbes R, et al. Procalcitonin as a diagnostic tool in lower respiratory tract infections and tuberculosis. Eur Respir J 2003;21:939-943.
51. Tateda K, Kusano E, Matsumoto T, et al. Semi-quantitative analysis of Streptococcus pneumoniae urinary antigen: Kinetics of antigen titers and severity of diseases. Scand J Infect Dis 2006;38:166-171.